Cromos Pharma, where the patients are

Biogen Idec

Icon’s Firecrest training recognized by TransCelerate BioPharma

Monday, April 14, 2014 10:13 AM

Icon,a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced that its Firecrest training meets TransCelerate BioPharma’s minimum criteria for International Conference on Harmonization Good Clinical Practice (ICH/GCP) training.

More... »

CRF Health eCOA webinar series

TrialNetworks wins Disruptive Technology and Innovator of the Year Award

Friday, April 11, 2014 11:37 AM

TrialNetworks and its Clinical Trial Optimization System won the Disruptive Innovator and Technology of the Year award from Partnerships in Clinical Trials 2014. The award honors an individual or a company with a new disruptive technology platform that has increased the efficiency and quality of clinical trials. TrialNetworks technology is used by companies including Merck, Biogen Idec, Ariad Pharmaceuticals and Infinity Pharmaceuticals to optimize clinical operations from startup through closeout.

More... »


FDA approves long-acting recombinant coagulation Factor IX concentrate for hemophilia B

Monday, March 31, 2014 01:10 PM

The FDA has approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding.

More... »

George A. Scangos to join Agilent Technologies board of directors

Thursday, March 20, 2014 12:00 PM

Agilent Technologies, a measurement and technology company focused on chemical analysis, life sciences, diagnostics, electronics and communications, has announced that George A. Scangos, Ph.D., CEO and director of Biogen Idec, has been appointed to Agilent’s board of directors and will join the board in September.

More... »

Eisai, Biogen Idec collaborate on Alzheimer’s disease treatments

Wednesday, March 5, 2014 01:12 PM

Eisai, a research-based pharmaceutical company, and Biogen Idec have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401. The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idec’s candidates for AD, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.

More... »

Ariad appoints Alexander J. Denner to board of directors

Monday, February 24, 2014 12:26 PM

Ariad Pharmaceuticals, an integrated global oncology company, has appointed Alexander J. Denner, Ph.D., to a two-year term on the company's board of directors, effective immediately. With the addition of Denner, who is the chief investment officer and founding partner of Sarissa Capital Management LP, the board now comprises nine directors, eight of whom are independent. The company also will appoint another independent director to the board, who will be selected by the board and be subject to Denner's concurrence.

More... »

NIH, industry and nonprofits join forces to speed validation of disease targets

Wednesday, February 5, 2014 01:02 PM

The National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations have launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.

More... »

TrialNetworks appoints Jorge G. Guerra advisory board chairman

Monday, January 20, 2014 01:32 PM

Jorge G. Guerra, M.D., has joined TrialNetworks as chairman of the advisory board. The TrialNetworks platform, which began as an innovative site engagement and communication portal, has rapidly grown into a comprehensive cloud-based solution for key aspects of a clinical trial from startup through closeout, including feasibility surveys, training, trial conduct efficiency, patient recruitment and retention, site activation and document management.

More... »

Proteostasis Therapeutics, Biogen Idec collaborate

Wednesday, December 11, 2013 11:33 AM

Proteostasis Therapeutics, developing novel therapeutics that regulate protein homeostasis aimed at helping to improve outcomes for patients with orphan and neurodegenerative diseases, has entered into a worldwide collaboration with Biogen Idec to research and develop therapeutic candidates based on the inhibition of Usp14.

More... »

Galapagos subsidiary BioFocus inks agreement with Biogen Idec

Wednesday, November 13, 2013 12:05 PM

Galapagos’ subsidiary BioFocus signed a three-year collaboration with Biogen Idec focused on the identification and validation of novel targets in scleroderma.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs